Kaiser Health News, November 28, 2016. Beyond the pharmaceutical industry, the bill’s supporters include universities, medical schools and groups representing them, as well as patient groups funded by drug and device companies. “It really is a David and Goliath issue of where the money is,” NCHR president Diana Zuckerman said.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Consumer Groups Caution Dems on ‘Cures’ Bill
The Hill, November 28, 2016. NCHR president Diana Zuckerman said the bill “makes it much easier to get FDA approval for things that may not work and may not be safe.”
Read More »Conservative and Progressive Experts Join Forces to Expose Under-the-Radar Consequences of 21st Century Cures Act
PR Newswire, November 22, 2016. Experts from opposite ends of the ideological spectrum were united over concern about the 21st Century Cures Act at an emergency briefing in the U.S. Senate yesterday. While highlighting different problems, they agreed that Congress should not rush a closed-door negotiated version of the bill during the lame-duck session.
Read More »Law Firm that Believes FDA is ‘Broken’ Highlights Cures Act Fears
Fierce Biotech, November 23, 2016. We know it’s a top priority for Congress, but a group of panelists speaking at an “emergency briefing” in the U.S. Senate this week hosted by an anti-FDA legal co have urged lawmakers to not “rush a closed-door negotiated version of the bill during the lame-duck session.”
Read More »Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices
The Health Care Blog, November 23, 2016. Find out why NCHR president is worried about the 21st Century Cures Act and cautions strongly against its hasty passage in lame-duck session.
Read More »